Evidence map›Paper›PMID 31707588›Full record

ReviewVirchows Archiv : an international journal of pathology2020

Secondary INI1-deficient rhabdoid tumors of the central nervous system: analysis of four cases and literature review.

Sumihito Nobusawa, Satoshi Nakata, Yuka Yoshida, Tatsuya Yamazaki, Keisuke Ueki, Keishiro Amano, Junkoh Yamamoto, Makiko Miyahara, Tsutomu Sugai, Yoichi Nakazato and 2 more

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Sumihito NobusawaDepartment of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan. nobusawa0319@gunma-u.ac.jp.ORCID http://orcid.org/0000-0001-9434-8400
Satoshi NakataDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Yuka YoshidaDepartment of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Tatsuya YamazakiDepartment of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Keisuke UekiDepartment of Neurosurgery, Dokkyo Medical University Hospital, Mibu, Japan.
Keishiro AmanoDepartment of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
Junkoh YamamotoDepartment of Neurosurgery, University of Occupational and Environmental Health, Kitakyushu, Japan.
Makiko MiyaharaDepartment of Neurosurgery, National Center for Global Health and Medicine, Tokyo, Japan.
Tsutomu SugaiDepartment of Neurosurgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Yoichi NakazatoDepartment of Pathology, Hidaka Hospital, Takasaki, Japan.
Junko HiratoDepartment of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Hideaki YokooDepartment of Human Pathology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma, 371-8511, Japan.
Gunma University · JPDokkyo Medical University · JPHidaka Hospital · JPJohns Hopkins University · USMie University · JPNational Center for Global Health and Medicine · JPUniversity of Occupational and Environmental Health Japan · JPYamagata Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atypical teratoid/rhabdoid tumors (AT/RT) are rare, highly malignant neoplasms of the central nervous system that predominantly occur in infants, and are characterized by the presence of rhabdoid cells and inactivation of INI1 or (extremely rarely) BRG1. The vast majority of AT/RT are recognized as primary tumors; however, rare AT/RT or INI1-deficient RT arising from other primary tumors have been reported. To better characterize secondary RT, we performed a histological and molecular analysis of four RT arising from pleomorphic xanthoastrocytoma (PXA), anaplastic PXA, low-grade astrocytoma, or ependymoma. Histologically, although conventional AT/RT are usually not largely composed of rhabdoid cells, three secondary RT were composed mainly of rhabdoid cells, two of which arising from (anaplastic) PXA exhibited marked nuclear pleomorphism reminiscent of that in the precursor lesions. Regarding INI1 alterations, although mutations including small indels are frequent in conventional AT/RT, only in one secondary RT had a mutation. Moreover, together with previously reported cases, biallelic INI1 inactivation in secondary RT was mostly due to biallelic focal and/or broad deletions. Although conventional AT/RT have stable chromosomal profiles, i.e., the frequency of copy number changes involving chromosomes other than chromosome 22 is remarkably low, our array comparative genomic hybridization analysis revealed numerous copy number changes in the secondary RT. In conclusion, secondary RT of the central nervous system are clinicopathologically and molecularly different from conventional pediatric AT/RT, and a nosological issue is whether these secondary RT should be called secondary "AT/RT" as most of the reported cases were.

Indexed as

AdultCentral Nervous System NeoplasmsFemaleHumansInfantMaleRhabdoid TumorSMARCB1 ProteinYoung AdultSMARCB1 ProteinSMARCB1 protein, humanAT/RTINI1Rhabdoid cellsSMARCB1

Identifiers

PMID31707588
OpenAlexW2984274093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.